ORPHAN DRUG AMENDMENT PROPOSAL REDUCES MARKET EXCLUSIVITY
Executive Summary
ORPHAN DRUG AMENDMENT PROPOSAL REDUCES MARKET EXCLUSIVITY to five years, but allows sponsors of products with "limited commercial potential" to apply for a five-year extension. The proposal was drafted by member companies of BIO, the merging Industrial Biotechnology Association and the Association of Biotechnology Companies, and circulated on Capitol Hill during the week of May 24. The industry proposal is prospective and is drafted to apply only to orphan products for which clinical trials have not yet begun. The draft provides that "no earlier than four years after approval" of an orphan drug, the sponsor could apply to FDA for a five-year extension of market exclusivity. To qualify for an extension, the product's patient population must be limited to 100,000 patients or fewer. The patient threshold for initial orphan designation is 200,000, as under current law. The proposal places the burden on the company to document that the product has "limited commercial potential," and competitors may submit evidence to the contrary. The draft notes that evidence might include the number of companies investigating the drug, the number of countries where a marketing application is pending and the prevalence of the indicated condition. Companies have been criticized for seeking orphan designations to obtain market exclusivity for biotechnology products that otherwise cannot qualify for patent protection. To address such situations, the industry draft proposes an alternative in which companies can obtain four-year market exclusivity for biotech products. The proposal defines a biotech product as a drug or biological product "primarily developed or manufactured using recombinant DNA technology, recombinant RNA technology, hybridoma technology, computer-aided amino acid sequence selection and identification or other processes involving site-specific genetic manipulation techniques, or...protein, peptide or biopolymer extracted from a cellular source." Under a proposed system that would parallel FDA's orphan drug procedures, the agency will not approve duplicates of a biotech drug or biological "for use in any disease or condition," regardless of the size of the patient population. FDA may approve competing versions under the proposal only if there are shortages of the first approved product during the four-year exclusivity period, the owner of the first product consents to marketing of the competing version, or the products were developed simultaneously. The draft defines products developed simultaneously as those for which marketing applications were submitted to FDA within 12 months of one another. The companies sent the proposal to Sens. Kennedy (D-Mass.), Metzenbaum (D-Ohio), Kassebaum (R-Kan.) and Hatch (R-Utah) and Reps. Waxman (D-Calif.) and Bliley (D-Va.). The industry reportedly is awaiting an indication of support from the legislators.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth